Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| QNTM | PRESS-RELEASE | neutral | 5/10 | Quantum BioPharma has closed the first tranche of its offering, raising $3.75 million through the issuance of 3,750 Debe | Mar 20, 2026 |
| ACRS | PRESS-RELEASE | neutral | 3/10 | Aclaris Therapeutics announced the presentation of new results from the open-label Phase 2a trial of ATI-2138, an invest | Mar 20, 2026 |
| RNXT | PRESS-RELEASE | neutral | 4/10 | RenovoRx announced it will host a conference call on March 30, 2026, to discuss its Q4 and full-year 2025 financial resu | Mar 20, 2026 |
| DARE | PRESS-RELEASE | neutral | 3/10 | Daré Bioscience announced a conference call to discuss its financial results for the year ended December 31, 2025. The p | Mar 20, 2026 |
| AVXL | PRESS-RELEASE | neutral | 5/10 | Anavex Life Sciences highlighted a newly published peer-reviewed study in PNAS Nexus that supports the role of autophagy | Mar 20, 2026 |
| MIST | PRESS-RELEASE | bullish | 8/10 | Milestone Pharmaceuticals (MIST) reported its 2025 financial results alongside a transformative year marked by FDA appro | Mar 20, 2026 |
| PHVS | PRESS-RELEASE | bullish | 8/10 | Pharvaris announced the publication of positive Phase 2 data from its CHAPTER-1 and RAPIDe-1 trials in The Lancet Haemat | Mar 20, 2026 |
| TEVA | PRESS-RELEASE | neutral | 3/10 | Teva Pharmaceutical announced the date for its Q1 2026 earnings release on April 29, 2026, and published an Aide Memoire | Mar 19, 2026 |
| GNLX | PRESS-RELEASE | mixed | 6/10 | Genelux reported its 2025 financial results, showing a narrowed net loss and increased R&D spend due to its Phase 3 ovar | Mar 19, 2026 |
| SLDB | PRESS-RELEASE | bullish | 8/10 | Solid Biosciences reported financial results for Q4 and full year 2025, highlighted by strong pipeline progress across i | Mar 19, 2026 |
| DMRA | PRESS-RELEASE | mixed | 6/10 | Damora Therapeutics reported its full-year 2025 financial results, showing a significant increase in net loss to $209.8 | Mar 19, 2026 |
| SLS | PRESS-RELEASE | mixed | 6/10 | SELLAS Life Sciences reported financial results for 2025, showing reduced net loss and a strong cash position bolstered | Mar 19, 2026 |
| RANI | PRESS-RELEASE | neutral | 3/10 | Rani Therapeutics announced it will release its Q4 and full-year 2025 financial results on March 26, 2026, followed by a | Mar 19, 2026 |
| ASMB | PRESS-RELEASE | bullish | 8/10 | Assembly Biosciences reported strong financial results for 2025, highlighted by a significant increase in collaboration | Mar 19, 2026 |
| MDGL | PRESS-RELEASE | neutral | 3/10 | Madrigal Pharmaceuticals granted 1,739 restricted stock units to seven new non-executive employees as inducement awards | Mar 19, 2026 |
| ALMS | PRESS-RELEASE | bullish | 8/10 | Alumis reported positive Phase 3 results for envudeucitinib in moderate-to-severe plaque psoriasis, demonstrating high s | Mar 19, 2026 |
| SGMO | PRESS-RELEASE | neutral | 3/10 | Sangamo Therapeutics announced it will release its Q4 and full-year 2025 financial results on March 30, 2026, followed b | Mar 19, 2026 |
| RLMD | PRESS-RELEASE | bullish | 8/10 | Relmada Therapeutics reported financial results for 2025 and provided a corporate update highlighting positive 12-month | Mar 19, 2026 |
| NCNA | PRESS-RELEASE | mixed | 6/10 | NuCana reported financial results for Q4 and full-year 2025, showing increased net losses but a strengthened cash positi | Mar 19, 2026 |
| SABS | PRESS-RELEASE | neutral | 5/10 | SAB Biotherapeutics (SABS) closed an underwritten public offering of 19,324,677 shares at $3.85 per share and pre-funded | Mar 19, 2026 |
| ABOS | PRESS-RELEASE | neutral | 4/10 | Acumen Pharmaceuticals announced it will report its Q4 and full-year 2025 financial results on March 26, 2026, along wit | Mar 19, 2026 |
| OKYO | PRESS-RELEASE | neutral | 3/10 | OKYO Pharma announced that Non-Executive Director John Brancaccio purchased 5,000 additional shares at $1.61, increasing | Mar 19, 2026 |
| BFRI | PRESS-RELEASE | bullish | 8/10 | Biofrontera Inc. reported strong fourth-quarter and full-year 2025 results, with record Q4 revenue of $17.1 million (up | Mar 19, 2026 |
| EVAX | PRESS-RELEASE | neutral | 2/10 | Evaxion announced the convening of its Annual General Meeting on April 16, 2026, to be held at its headquarters in Denma | Mar 19, 2026 |
| SLGL | PRESS-RELEASE | neutral | 4/10 | Sol-Gel Technologies filed its 20-F for 2025, disclosing audited financial results and providing corporate updates. The | Mar 19, 2026 |
| MBRX | PRESS-RELEASE | mixed | 6/10 | Moleculin Biotech reported financial results for 2025, showing a net loss of $33.6 million and reduced R&D spending. The | Mar 19, 2026 |
| HUMA | PRESS-RELEASE | mixed | 5/10 | Humacyte announced a $1.475 million binding purchase commitment for its Symvess product to support a clinical evaluation | Mar 19, 2026 |
| MREO | PRESS-RELEASE | mixed | 6/10 | Mereo BioPharma reported its 2025 financial results, showing a narrower net loss of $41.9 million compared to $43.3 mill | Mar 19, 2026 |
| QNRX | PRESS-RELEASE | neutral | 3/10 | Quoin Pharmaceuticals announced it will release its Q4 and full-year 2025 financial results and provide a corporate upda | Mar 19, 2026 |
| TSHA | PRESS-RELEASE | mixed | 6/10 | Taysha Gene Therapies reported financial results for 2025 and provided a corporate update highlighting progress in its T | Mar 19, 2026 |